Demecan key facts
- Producer and supplier of cannabis intended to be used for medicinal drug research and development process.
- Demecan’s last known valuation is $108.8M.
- It has raised $23.4M; the latest was Later Stage VC in Aug 2024.
- Notable investors include b2venture, BMH Beteiligungs-Managementgesellschaft Hessen, Trog Hawley Capital, PHK Enterprise Family Office, Enexis (Sweden) — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Demecan: the Monday email on marks, rounds and moves
Demecan funding rounds
No funding rounds for Demecan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Demecan valuation
Demecan's last known valuation is $109 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Demecan investors
10 investors are on record for Demecan, including b2venture, BMH Beteiligungs-Managementgesellschaft Hessen, Trog Hawley Capital and PHK Enterprise Family Office.
About Demecan
Producer and supplier of cannabis intended to be used for medicinal drug research and development process. The company specializes in the cultivation and processing of medical cannabis plants that are grown using sterilized water from a pharmaceutical reverse osmosis system indoors under complete climate control, enabling clients in the healthcare industry to avail clean and natural cannabis without pesticides and irradiation.
- Sector
- Healthcare
- HQ
- Ebersbach, Germany
- Founded
- 2017
- Employees
- 63
- Website
- demecan.de/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Demecan’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.